secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orchestra BioMed Holdings, Inc. (OBIO)
CIK:        0001814114
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001104659-25-009393
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orchestra BioMed appoints former Medtronic SVP Chris Cleary to board; Dr. Eric Rose resigns as director
--------------------------------------------------------------------------------

- Chris Cleary appointed as Class II independent director effective Jan 30, 2025; board expanded to nine.
- Cleary was Medtronic SVP of Corporate Development, led $50B Covidien acquisition and $6B asset sale to Cardinal Health.
- Cleary previously helped shape Orchestra BioMed's AVIM therapy strategic collaboration with Medtronic.
- Eric Rose resigned as director Feb 3, 2025; remains as Emeritus Board Member and Strategic Advisor.
- Board expected to decrease to eight members following Rose resignation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814114/000110465925009393/0001104659-25-009393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814114/000110465925009393/tm255461d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-009393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer